resectability between before and after CRT in 223 PDAC patients resected after CRT Variables before CRT n223 After CRT n223 Pvalue CEA median range ngml n214 40 09805 ID: 1041571
Download Presentation The PPT/PDF document "Electronic supplementary Material 1. Com..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Electronic supplementary Material 1. Comparison of tumor makers and variables on CT including TNM classification and resectability between before and after CRT in 223 PDAC patients resected after CRTVariablesbefore CRT (n=223)After CRT (n=223)P-valueCEA, median (range), ng/ml (n=214) *4.0 (0.9-80.5)3.4 (0.7-53.2)<0.001CA19-9, median (range), U/L (n=208) #179.5 (3-17268.9)40.8 (0.1-2406.3)<0.001Tumor size, median (range), mm30 (6.9-76)27 (10-82)<0.001Tumor size (<=20/>20 and <=40/>40 mm)34/155/3455/142/260.037CH (0/1)109/114106/1170.776DU (0/1)143/80142/810.921S (0/1)45/17844/1790.906RP (0/1)41/18236/1870.531PVp (0/1)159/64161/620.833PVsm (0/1)132/91138/850.561PVsp (0/1)138/85138/851.000Asm (0/1)191/32190/330.893Ace (0/1)195/28192/310.675Ach (0/1)181/42177/470.554Asp (0/1)168/55166/570.827PL (0/1)99/12493/1300.566OO (0/1)180/43180/431.000T category based on JPS (T1a/T1b/T1c/T2/T3/T4)0/0/2/1/119/1010/0/2/1/114/1060.973T category based on AJCC (T1a/T1b/T1c/T2/T3/T4)0/0/25/75/14/1090/1/39/61/8/1140.123N category based on JPS (N0/N1a/N1b)178/41/4202/17/40.003N category based on AJCC (N0/N1/N2)178/41/4202/17/40.003Stage based on JPS (IA/IB/IIA/IIB/III)0/0/105/17/1011/0/110/6/196<0.001Stage based on AJCC (IA/IB/IIA/IIB/III)22/65/10/15/11140/57/6/3/1170.005Resectability based on JPS (R/BR-PV/BR-A/UR-LA)79/33/39/7280/28/40/750.921CT: computed tomography, PDAC: pancreatic ductal adenocarcinoma, CRT: chemoradiotherapy, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, CH: bile duct invasion, DU: duodenal invasion, S: serosal side of the anterior pancreatic invasion, RP: retropancreatic tissue invasion, PVp/sm/sp: portal venous system invasion portal vein/superior mesenteric vein/splenic vein, Asm/ce/ch/sp: arterial system invasion superior mesenteric artery/celiac artery/common hepatic artery/splenic artery, PL: extrapancreatic nerve plexus invasion, OO: invasion to other organs, 0:absent, 1: present, JPS: the seventh edition of General Rules for the Study of Pancreatic Cancer published by the Japan Pancreas Society, AJCC: the eighth edition of The American Joint Committee on Cancer, R: resectable, BR-PV: borderline resectable (SMV/PV invasion alone), BR-A: borderline resectable (arterial invasion), UR-LA: locally advanced unresectablePDAC: pancreatic ductal adenocarcinoma, CRT: chemoradiotherapy, BMI: body mass index, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, Ph: pancreatic head, Pb: pancreatic body, Pt: pancreatic tail, CT: computed tomography, GEM: gemcitabine, GS: S1+gemcitabine* CEA levels were not measured after CRT in 9 patients.# CA19-9 levels were calculated by excluding the Lewis antigen-negative patients.